Company intelligence / Profile preview

Elicera Therapeutics AB

Ownership: Private
Employees: ~2
Development stage: Phase 1

Overview

Elicera Therapeutics has two main technology areas—CAR T-cell therapies and oncolytic viruses—both enhanced by its iTANK platform. Its lead oncolytic virus candidate, ELC‑100, received Orphan Drug Designation from the FDA for pancreatic neuroendocrine tumors; final data from the first part of its ongoing Phase I/II trial are expected mid‑2025. The lead CAR T program, ELC‑301 for B-cell lymphoma, showed a complete response in the first patient at lowest dose level with very mild side effects in early clinical results. The company also has preclinical programs targeting solid cancers and brain tumors[6][7].

Therapeutic areas: Oncology
Modalities: CAR T-cell therapies (cell therapy)Oncolytic viruses (gene therapy)
Industry: Biotech

Drug pipeline

5 assets

ELC-301

4 more assets in the full pipeline.

Partnerships

Vecura R&D division at Karolinska University HospitalUppsala University for automated production of ELC–401Swedish Cancer Society support for clinical study planning[3]

Beyond the preview

Go deeper on Elicera Therapeutics AB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Elicera Therapeutics AB.